Super-Pulsed Thulium Fiber Laser Versus Holmium:YAG Laser in Retrograde Intrarenal Surgery for Upper Ureteral and Renal Stones
Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Jun 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two types of lasers used in a procedure called retrograde intrarenal surgery (RIRS) to treat kidney and ureter stones, which are hard deposits that can cause pain and other issues. The traditional method uses a holmium laser, while this study is investigating a newer option called the super-pulsed thulium fiber laser. The goal is to find out which laser is more effective and safe for removing stones that are between 10 and 25 millimeters in size.
To participate in this trial, individuals need to be between 18 and 75 years old and have been diagnosed with kidney or upper ureter stones confirmed by a CT scan. They should be able to undergo surgery and be willing to sign a consent form. Participants will be randomly assigned to receive treatment with either the thulium laser or the holmium laser. This research aims to provide valuable information that could help shape future treatment guidelines for patients with urinary stones. If you're considering joining, it's important to know that there are specific health conditions that could exclude someone from participating, such as uncontrolled infections or certain medical illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 ≤ Age ≤ 75 years old, regardless of gender, able to tolerate surgery;
- • 2. Patients who have been confirmed by bilateral renal/urinary tract CT to have upper ureteral or renal stones, single or multiple, and are planning to undergo ureteroscopic lithotripsy for stone removal;
- • 3. Confirmed by bilateral renal/urinary tract CT, the cumulative maximum diameter of stones is 10mm\<cumulative maximum diameter ≤ 25mm;
- • 4. Those who voluntarily participate and sign an informed consent form.
- Exclusion Criteria:
- • 1. Uncontrollable systemic hemorrhagic disease;
- • 2. Severe spinal deformities, severe hip joint deformities, and difficulty in lithotomy position;
- • 3. Uncontrolled urinary tract infections;
- • 4. Any intracavitary surgery caused by anatomical factors of the urinary system cannot be performed;
- • 5. Pregnant, planned pregnancy within 3 months, and lactating female patients;
- • 6. The patients determined by the investigator to be unsuitable for this study include (but are not limited to): known to have human immunodeficiency virus (HIV) or AIDS; Suffering from mental illness; Infectious diseases;
About Sun Yat Sen Memorial Hospital Of Sun Yat Sen University
Sun Yat-sen Memorial Hospital of Sun Yat-sen University is a leading academic medical institution located in Guangzhou, China, renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields, including oncology, cardiology, and infectious diseases, to conduct rigorous studies aimed at improving treatment outcomes and enhancing patient welfare. With a focus on collaboration and scientific excellence, the hospital is dedicated to translating research findings into practical applications that benefit both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Kewei Xu, MD, PhD
Principal Investigator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported